Action over generic Lipitor may subject FDA to congressional probe

12/2/2012 |

The FDA's disclosure that a shortage of a generic version of cholesterol drug Lipitor is "not anticipated" may be an invitation for Congress to take up work on the drug-shortage legislation and investigate the FDA for allowing Ranbaxy Laboratories to produce and sell a generic Lipitor, RPM Report's Michael McCaughan said. Ranaxby's issues with production raise questions whether the FDA bargained hard enough if patient safety and the supply chain's integrity were the top goals.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR